The emergence of dual-action receptor agonists in the management of type 2 diabetes and obesity has sparked considerable interest, particularly regarding retatrutide and tirzepatide. While both medications target both the GLP-1 and GIP receptors, subtle yet potentially significant differences exist in their pharmacological profiles. Retatrutide, a